To date, no head-to-head trials have compared the e cacy of brigatinib and alectinib
against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-naïve,
advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
We conducted an indirect treatment comparison (ITC) between brigatinib and alectinib, with crizotinib
as a common comparator, using a Bayesian model with non-informative prior distribution and assessed
the between-study heterogeneity of the studies. The primary e cacy endpoint was progression-free
survival (PFS), and e cacy was ranked using the surface under the cumulative ranking (SUCRA)
curve values. ITC analysis showed that there were no significant di erences in PFS between the
brigatinib and alectinib arms. However, the SUCRA values revealed that alectinib ranked the highest
by e cacy in the overall patient population, whereas brigatinib ranked the highest by e cacy in
the CNS metastasis sub-group. Although there wer..... READ ARTICLE
Cancers DOI:10.3390/cancers12040942
Authors: Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino,
Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka , Akihiko Tanaka,
Tohru Ohmori,Hironori Sagara
